journal cover

Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

Journal for Immunotherapy of Cancer

Jan 1, 2013

M OhnoHideho Okada

Abstract

Expression of miR-17-92 enhances T-cell survival and interferon (IFN)-γ production. We previously reported that miR-17-92 is down-regulated in T-cells derived from glioblastoma (GBM) patients. We hypothesized that transgene-derived co-expression of miR17-92 and chimeric antigen receptor...read more

Mentioned in this Paper

EEF1A1 gene
EGFR gene
TNFRSF9 gene
ADA Transduced T Cell
Interferon Signaling Modulation Pathway
Protein Domain
In Vivo
CD137 antigen
Interferons
Viral Vector
56
Paper Details
References
  • References42
  • Citations26
12345
  • References42
  • Citations26
123

Similar Papers Found In These Feeds

Interferon Signalling

Via interaction with their specific receptors, interferons (IFNs) activate signal transducer and activator of transcription (STAT) complexes. STAT activation initiates the classical Janus kinase-STAT (JAK-STAT) signaling pathway. In this pathway, JAKs associate with IFN receptors and, following receptor engagement with IFN, phosphorylate both STAT1 and STAT2. As a result, an IFN-stimulated gene factor 3 (ISGF3) complex forms—this contains STAT1, STAT2 and a third transcription factor called IRF9—and moves into the cell nucleus. Inside the nucleus, the ISGF3 complex binds to specific nucleotide sequences called IFN-stimulated response elements (ISREs) in the promoters of certain genes, known as IFN stimulated genes. Discover the latest research on interferon signalling here.

Glioma Cells

T cells: Costimulatory Receptors

T cell activation requires engagement of both the T cell receptor and a co-stimulatory molecule. Lack of a co-stimulatory signal can result in T cell anergy, deletion, or immune tolerance. Find the latest research on T cell co-stimulatory receptors here.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is a tumor that develops from astrocytes and oligodendrocytes. Here is the latest research on mechanisms that underlie GBM and associated therapeutic approaches.

Signaling Pathways in Glioblastoma

Glioblastoma is a malignant brain tumor with mutations in various signaling pathways involved in tumorigenic processes. Developing therapeutic agents against these signaling pathways are ongoing. Discover the latest research on signaling pathways in glioblastoma.

© 2020 Meta ULC. All rights reserved

Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

Journal for Immunotherapy of Cancer

Jan 1, 2013

M OhnoHideho Okada

PMID: 24829757

DOI: 10.1186/2051-1426-1-21

Abstract

Expression of miR-17-92 enhances T-cell survival and interferon (IFN)-γ production. We previously reported that miR-17-92 is down-regulated in T-cells derived from glioblastoma (GBM) patients. We hypothesized that transgene-derived co-expression of miR17-92 and chimeric antigen receptor...read more

Mentioned in this Paper

EEF1A1 gene
EGFR gene
TNFRSF9 gene
ADA Transduced T Cell
Interferon Signaling Modulation Pathway
Protein Domain
In Vivo
CD137 antigen
Interferons
Viral Vector
56

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References42
  • Citations26
12345
  • References42
  • Citations26
123
/papers/expression-of-mir-17-92-enhances-anti-tumor/24829757